| ₹ crore | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue | 612 | 691 | −11.5% |
| EBITDA | 67.6 | 84.6 | −20.1% |
| EBITDA margin | 11.1% | 12.2% | −1.2 pts |
| Profit before tax | 58.5 | 77.3 | −24.2% |
| Net profit | 43.9 | 58.1 | −24.5% |
| EPS | ₹15.08 | ₹19.97 | −24.5% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 1,491 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 91.7 | 91.7 | 65.5 | 61.2 | 18.6 | ||
| 144 | 144 | 99.6 | 83.2 | 159 | ||
| 1,544 | — | — | — | — | ||
| 2,060 | 2,140 | 2,000 | 1,966 | 1,801 | ||
| — | +7.0% | +1.7% | +9.2% | — | ||
| 210 | 227 | 221 | 163 | 122 | ||
| 10.2% | 10.6% | 11.1% | 8.3% | 6.8% | ||
| 172 | 192 | 192 | 133 | 95.8 | ||
| 125 | 139 | 142 | 102 | 63.2 | ||
| 6.1% | 6.5% | 7.1% | 5.2% | 3.5% | ||
| ₹43.02 | ₹47.91 | ₹48.81 | ₹35.18 | ₹21.72 | ||
| — | −1.8% | +38.7% | +61.9% | — | ||
| — | 100 | 93.5 | 184 | −10.6 | ||
| — | −94.6 | −37.3 | −49.0 | −87.5 | ||
| 5.7 | 5.7 | 56.2 | 135 | −98.1 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 1,491.1 | |
| - Cash, Equiv & ST Investments | 18.6 | 61.2 | 65.5 | 91.7 | 91.7 | |
| + Total Debt | 159.1 | 83.2 | 99.6 | 144.3 | 144.3 | |
| Enterprise Value | — | — | — | — | 1,543.7 | |
| Revenue | 1,801.3 | 1,966.4 | 1,999.9 | 2,140.0 | 2,060.4 | |
| Growth %, YoY | — | +9.2 | +1.7 | +7.0 | — | |
| EBITDA | 121.9 | 162.6 | 221.2 | 227.0 | 210.1 | |
| Margin % | 6.77 | 8.27 | 11.06 | 10.61 | 10.20 | |
| EBIT | 95.8 | 133.3 | 192.1 | 191.6 | 172.2 | |
| Net Income | 63.2 | 102.4 | 142.0 | 139.4 | 125.2 | |
| Margin % | 3.51 | 5.21 | 7.10 | 6.51 | 6.08 | |
| EPS, Adj (current shares) | 21.72 | 35.18 | 48.81 | 47.91 | 43.02 | |
| Growth %, YoY | — | +61.9 | +38.7 | -1.8 | — | |
| Cash from Operations | -10.6 | 183.7 | 93.5 | 100.2 | — | |
| Capital Expenditures | -87.5 | -49.0 | -37.3 | -94.6 | — | |
| Free Cash Flow | -98.1 | 134.7 | 56.2 | 5.7 | 5.7 | |
Prices at the previous close · figures from the company's filings with NSE
Insecticides (NSE: INSECTICID) had a market capitalisation of ₹1,491 crore at the previous close (₹512.45 a share), a PE ratio of 11.9 on the last four quarters' profit and a price-to-book ratio of 1.22. In FY26 its consolidated net profit was ₹139 crore on revenue of ₹2,140 crore; in Q1 FY27 (April–June 2026) it was ₹43.9 crore, down 24.5% year on year. Its debt-to-equity ratio was 0.12 on 31 March 2026. Promoters held 72.30% of the shares on 30 September 2026.
Insecticides' PE ratio is 11.9 at the previous close (₹512.45 a share): a market capitalisation of ₹1,491 crore divided by consolidated net profit of ₹125 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹139 crore) it is 10.7.
Insecticides' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,220 crore on 31 March 2026, up 12.5% from ₹1,085 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,491 crore at the previous close.
Insecticides' book value per share was ₹419.42 on 31 March 2026: shareholders' equity of ₹1,220 crore divided by the 2.91 crore shares in issue, up 12.6% from ₹372.43 a year earlier. The share price at the previous close was ₹512.45.
Insecticides' price-to-book (PB) ratio is 1.22 at the previous close: a market capitalisation of ₹1,491 crore divided by shareholders' equity (book value) of ₹1,220 crore on 31 March 2026. That is a book value of ₹419.42 per share against a share price of ₹512.45.
In FY26, Insecticides' return on equity (ROE) was 12.1% and its return on capital employed (ROCE) was 16.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 13.5% and ROCE 17.6%.
Insecticides' dividend yield is 0.39% at the previous close: dividends of ₹2 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹512.45. They were ₹2 on 6 February 2026 (interim).
Insecticides' market capitalisation was ₹1,491 crore at the previous close: 2.91 crore shares at ₹512.45 each.
Insecticides' basic earnings per share (EPS) were ₹47.91 in FY26, against ₹48.38 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹43.01.
In 2026, Insecticides has declared one dividend: ₹2 (interim) with record date 6 February 2026.
No. Insecticides had borrowings of ₹144 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.12. Its cash and current investments were ₹91.8 crore, so its net debt was ₹52.4 crore.
Insecticides' debt-to-equity ratio was 0.12 on 31 March 2026: borrowings of ₹144 crore against total equity of ₹1,220 crore. A year earlier, on 31 March 2025, it was 0.09.
Promoters held 72.30% of Insecticides on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
On 30 September 2026, Insecticides' shares were held by promoters 72.30%, foreign portfolio investors (FII/FPI) 4.44%, domestic institutions (DII) 9.26% (including mutual funds at 8.93%) and retail and other non-institutional investors 14.00%. Over the year, FII holding was down 0.07 percentage points from 4.51% and DII holding was down 0.24 percentage points from 9.50%.
Insecticides' latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net profit ₹43.9 crore, down 24.5% from ₹58.1 crore in Q1 FY26; revenue from operations ₹612 crore, down 11.5% year on year.
In FY26 (April 2025–March 2026), Insecticides' consolidated net profit was ₹139 crore, down 1.8% from ₹142 crore in FY25, on revenue from operations of ₹2,140 crore (up 7.0%). Over three years, from FY23, net profit was up 120.5%.
In FY26, Insecticides generated ₹100 crore of cash from operations and spent ₹94.6 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹5.7 crore. In FY25 it was ₹56.2 crore.
Insecticides will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.
In FY26, Insecticides earned net profit of ₹139 crore on revenue of ₹2,140 crore, against ₹120 crore on ₹1,057 crore for India Pesticides. Insecticides' operating margin was 9.0% (India Pesticides 14.4%) and its return on equity 12.1% (India Pesticides 12.6%).
On FY26 consolidated figures, against India Pesticides, Meghmani Organics and Bharat Rasayan: Insecticides' operating margin of 9.0% is the third highest of the four (India Pesticides 14.4%, Meghmani Organics 2.6%, Bharat Rasayan 13.9%; peer average 10.3%); its return on equity of 12.1% is the third highest of the four (India Pesticides 12.6%, Meghmani Organics 1.9%, Bharat Rasayan 12.1%; peer average 8.9%); its revenue growth over three years of 5.9% a year is the second highest of the four (India Pesticides 6.1% a year, Meghmani Organics −5.2% a year, Bharat Rasayan 0.2% a year; peer average 0.4% a year).
From Insecticides' own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.